Article

New CPT code released for AMD treatment

A new Category III CPT code was released by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel.

Freemont, CA-A new Category III CPT code was released by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel. The code for Neovista Inc.'s radiation therapy for the treatment of wet age-related macular generation (AMD) (0190T) will become effective July 1 and will be used with the code for performing a basic posterior vitrectomy (67036).

"We at NeoVista believe that our unique radiation therapy will eventually be shown to offer a less-time-consuming and less-costly alternative for physicians who treat patients with wet AMD," said John Hendrick, president and chief executive officer of NeoVista. "Obtaining a Category III CPT code is a vital step towards our end-goal of seeing our therapy through to market launch, where it will be of help to millions of people suffering from wet AMD."

The code will eventually allow physicians to identify the novel epiretinal radiation treatment for wet AMD on insurance claims.

The American Academy of Ophthalmology and American Society of Therapeutic and Radiation Oncology supported Neovista through the code development.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.